JonesTrading Reaffirms Their Buy Rating on T2 Biosystems (TTOO)


In a report released today, Soumit Roy from JonesTrading reiterated a Buy rating on T2 Biosystems (TTOO). The company’s shares closed last Tuesday at $1.27.

According to TipRanks.com, Roy is a 5-star analyst with an average return of 36.2% and a 58.4% success rate. Roy covers the Healthcare sector, focusing on stocks such as Deciphera Pharmaceuticals, Adaptimmune Therapeutics, and Monopar Therapeutics Inc.

T2 Biosystems has an analyst consensus of Moderate Buy.

See today’s analyst top recommended stocks >>

The company has a one-year high of $3.21 and a one-year low of $0.24. Currently, T2 Biosystems has an average volume of 10.74M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

T2 Biosystems, Inc. engages in the development of proprietary technology platform. It offers the T2 Magnetic Resonance technology which enables rapid detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types. It products include T2Bacteria Panel, T2Candida Panel, T2Dx Instrument, AND T2MR Technology. The company was founded by Michael J. Cima, Robert S. Langer Jr., Tyler Jacks, Lee Josephson, W. David Lee, and Ralph Weissleder on April 27, 2006 and is headquartered in Lexington, MA.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts